SCHEMBL22233992

SCHEMBL22233992

Nc1c(-c2ccccc2)cc([N+](=O)[O-])c2ccccc12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTSB P07858 2/20 0.61
▸ ALDH1A1 P00352 5/20 0.53
▸ TDP1 Q9NUW8 4/20 0.53
▸ HPRT1 P00492 2/20 0.46
▸ CRHBP P24387 1/20 0.45
▸ CRHR2 Q13324 1/20 0.45
▸ TSHR P16473 1/20 0.44
▸ MAPT P10636 4/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ S1PR4 O95977 1/20 0.43
▸ S1PR1 P21453 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.43
▸ MEN1 O00255 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ PSMD14 O00487 1/20 0.42
▸ PRKACA P17612 1/20 0.42
▸ CASP6 P55212 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31521564 0.85 CTSB (0.55) CTSBALDH1A1TDP1HPRT1CRHBP
SCHEMBL22234100 0.84 CTSB (0.51) CTSBALDH1A1TDP1HPRT1TSHR
SCHEMBL22233986 0.84 CTSB (0.51) CTSBALDH1A1TDP1TSHRMAPT
SCHEMBL22234248 0.81 CTSB (0.48) CTSBALDH1A1TDP1HPRT1TSHR
SCHEMBL8687725 0.80 CTSB (0.77) CTSBALDH1A1TDP1HPRT1TSHR
SCHEMBL28274440 0.80 TDP1 (0.53) CTSBALDH1A1TDP1HPRT1CRHBP
SCHEMBL9386016 0.79 CTSB (0.69) CTSBALDH1A1TDP1HPRT1TSHR
SCHEMBL15461976 0.78 ALDH1A1 (0.69) ALDH1A1TDP1HPRT1CRHBPCRHR2
SCHEMBL7657590 0.77 TDP1 (0.58) ALDH1A1TDP1HPRT1CRHBPCRHR2
SCHEMBL3924698 0.77 ALDH1A1 (0.54) CTSBALDH1A1TDP1CRHBPCRHR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12122742-B2 Small molecule direct inhibitors of KEAP1-NRF2 protein-protein interaction RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2024-10-22 — — US disclosed
US-20220112160-A1 SMALL MOLECULE DIRECT INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2022-04-14 — — US disclosed
WO-2020150446-A1 SMALL MOLECULE DIRECT INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2020-07-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220112160-A1 SMALL MOLECULE DIRECT INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION KEAP1, NFE2L2, HMOX1 CTSB 3717/4885ALDH1A1 1856/4885TDP1 4531/4885
US-12122742-B2 Small molecule direct inhibitors of KEAP1-NRF2 protein-protein interaction KEAP1, NFE2L2, HMOX1 CTSB 3717/4885ALDH1A1 1856/4885TDP1 4531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback